Welcome to our dedicated page for Repare Therapeutics SEC filings (Ticker: RPTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Repare Therapeutics Inc. filings document the company's transition from a Nasdaq-listed clinical-stage precision oncology issuer to an acquired company with common shares removed from exchange listing and Exchange Act reporting obligations terminated or suspended. The record includes 8-K disclosures for shareholder voting on a Québec plan of arrangement, completion of the acquisition, material agreements, governance and compensation matters, clinical Regulation FD disclosure for the RP-1664 LIONS trial, and reported operating results.
Form 25 and Form 15 filings document the removal of Repare common shares from Nasdaq listing and the termination or suspension of Exchange Act registration and reporting duties. Earlier disclosures also identify the company's common-share capital structure, proxy matters, governance actions, and corporate-status reporting.
Repare Therapeutics Inc. filed a current report to note that it issued a press release on August 8, 2025 detailing recent business highlights and its financial results for the three and six months ended June 30, 2025. The press release is attached as Exhibit 99.1 and is incorporated by reference into this report.
The company clarifies that the information in this report and the accompanying exhibits is not automatically incorporated into other Securities Act or Exchange Act filings unless specifically referenced, and that information on its website is not part of this disclosure.
Repare Therapeutics Inc. (Nasdaq: RPTX) filed a Form 8-K to disclose changes approved by its Compensation Committee on June 13, 2025 to the severance package of Michael Zinda, Ph.D., Executive Vice President & Chief Scientific Officer.
Under the amended terms, if Dr. Zinda is terminated without “cause” or resigns for “good reason,” and the separation is not in connection with a change-in-control, he will receive:
- Lump-sum cash equal to nine months of current base salary.
- COBRA premiums paid by Repare for up to 12 months post-separation.
- Accelerated vesting of all unvested equity awards for nine months from the separation date.
- Pro-rated target bonus for the year of separation, paid in a lump sum.
If a change in control occurs within 90 days after the separation date, Dr. Zinda will instead receive the enhanced change-in-control severance stipulated in Section 5.7(c) of his previously disclosed Employment Agreement. All other existing severance protections in that agreement remain unchanged.
The disclosure is limited to executive compensation; no financial results, operational updates, or strategic transactions were reported.